Beckman Coulter Life Sciences Acquires Labcyte to Expand Laboratory Automation Business.
M2 EQUITYBITES-January 31, 2019-Beckman Coulter Life Sciences Acquires Labcyte to Expand Laboratory Automation Business
(C)2019 M2 COMMUNICATIONS http://www.m2.com
31 January 2019 - US-based biomedical laboratory instruments provider Beckman Coulter Life Sciences has acquired California, US-based acoustic liquid handling firm Labcyte, the company said.
Labcyte is best known for its Echo acoustic droplet ejection technology, which uses sound waves to transfer tiny amounts of liquid with unequalled speed and accuracy.
This technology, the centerpiece of Labcyte's Echo Liquid Handlers, enables walkaway convenience and integration capabilities.
According to Beckman Coulter, Labcyte technology enables faster and more cost-effective laboratory workflows in applications such as drug discovery and genomics.
Labcyte will transition into Beckman Coulter Life Sciences under the larger Danaher Life Sciences platform of companies, which generates approximately USD 6.5bn in annual revenue.
Beckman Coulter Life Sciences develops, manufactures and markets products that simplify, automate and innovate complex biomedical testing.
For more than 75 years, our products have been making a difference in people's lives by improving the productivity of medical professionals and scientists, supplying critical information for improving patient health and delivering trusted solutions for research and discovery.
Scientists use our life science research instruments to study complex biological problems including causes of disease and potential new therapies or drugs.
Labcyte, a global biotechnology tools company headquartered in San Jose, California, is advancing liquid handling. Echo Liquid Handlers use sound to precisely transfer liquids without contact, eliminating the use of pipettes.
Labcyte instruments are used worldwide throughout the pharmaceutical and biotechnology industries, as well as by hospitals, service laboratories, contract research organisations, and academic institutions. Our customers work across a range of scientific research, including drug discovery, genomics, proteomics, diagnostics and personalised medicine. Labcyte has 63 US patents and others internationally.
((Comments on this story may be sent to firstname.lastname@example.org))